In addition to the well-established core AD CSF biomarkers like Aβ and tau proteins, a number of candidate molecules have been investigated as potential AD biomarker, mainly related with pathological mechanisms or to other aspects of the disease pathophysiology, such as enzymatic deficits, degrading pathway, biochemical modifications or clearance. Here, MAPT is linked to Alzheimer disease.